Search
  • scottlissington

Te Arai Rare Disorders Medicines recommended for PHARMAC funding

The PHARMAC Rare Disorders Subcommittee met November 5 and 6 2018 to consider the funding of Medicines for the treatment of Rare Disorders. Rare Disorders are defined as those affecting less than 1 in 50,000 New Zealanders, often these Medicines are referred to a Orphan Medicines. The subcommittee can recommend a Medicine is funded, decline funding or defer a decision to a later date.

Of the total 11 Medicines considered two Te Arai BioFarma Medicines received a recommendation for funding with a high priority: Carglumic acid (for the treatment of metabolic disorders CPS1 and  NAGs) and nitisinone (for the treatment of hereditary type 1 tyrosinaemia). Two further Medicines were recommended for funding with a medium priority for the treatment of cystic fibrosis and fabry disease. The remaining Medicines were declined (6) or deferred (1).

The complete subcommittee minutes are available here :  Nov 5 and 6 2018


2 views0 comments

Recent Posts

See All

MacroBID Dear Healthcare Professional Letter

Please find the "Dear Healthcare Professional Letter" containing additional information about the release characteristics and in-use shelf life of Macrobid® (nitrofurantoin macrocrystals/nitrofurantoi